Purdue Pharma Proposes $7.4 Billion Settlement Plan for Opioid Crisis Lawsuits

The plan includes up to $7 billion from the Sackler family, victim compensation, and Purdue's transformation into a public benefit company.

The new settlement plan offers creditors the choice to opt in for payments or opt out to retain the right to sue the Sackler family.
The Sackler family is contributing between $6.5 billion and $7 billion, a $1 billion increase compared to the previous plan rejected by the Supreme Court.
Purdue Pharma will be dissolved and replaced by a public benefit company focused on addressing the opioid crisis and producing low-cost naloxone.
The plan allocates $850 million for individual victims, including those addicted to OxyContin and babies born with withdrawal symptoms.
Creditor voting on the plan is expected to begin in May 2025, with final approval contingent on a U.S. bankruptcy judge’s decision.